Chemoprevention of bladder cancer

BJU International

Volumn 102, Issue 9B, 2008, Pages 1274-1278

  La Rochelle, Jeffrey ^a   Kamat, Ashish ^b   Grossman, H Barton ^b   Pantuck, Allan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; BIOLOGICAL MARKER; CAROTENOID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DIMETHYL SULFOXIDE; EFLORNITHINE; ETRETINATE; FENRETINIDE; INDOMETACIN; PIROXICAM; PYRIDOXINE; RETINOID; RETINOL; VITAMIN B GROUP; ZINC;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER SURGERY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG SAFETY; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RECTUM POLYP; REVIEW; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIALS AS TOPIC; CYCLOOXYGENASE 2 INHIBITORS; EFLORNITHINE; HUMANS; RISK FACTORS; SMOKING; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; VITAMINS;

EID: 54049156070     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07970.x     Document Type: Review

References (41)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007 57 : 43 66
2. Avritscher EB, Cooksley CD, Grossman HB et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 2006 68 : 549 53
3. Wynder EL, Goldsmith R. The epidemiology of bladder cancer: a second look. Cancer 1977 40 : 1246 68
4. Hoover R, Cole P. Population trends in cigarette smoking and bladder cancer. Am J Epidemiol 1971 94 : 409 18
5. Curigliano G, Zhang YJ, Wang LY et al. Immunohistochemical quantitation of 4-aminobiphenyl-DNA adducts and p53 nuclear overexpression in T1 bladder cancer of smokers and nonsmokers. Carcinogenesis 1996 17 : 911 6
6. Brennan P, Bogillot O, Cordier S et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer 2000 86 : 289 94
7. Cao W, Cai L, Rao JY et al. Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma. Cancer 2005 104 : 2400 8
8. Vineis P, Caporaso N, Tannenbaum SR et al. Acetylation phenotype, carcinogen-hemoglobin adducts, and cigarette smoking. Cancer Res 1990 50 : 3002 4
9. Silverman DT, Levin LI, Hoover RN, Hartge P. Occupational risks of bladder cancer in the United States. I. White men. J Natl Cancer Inst 1989 81 : 1472 80
10. Chiou HY, Chiou ST, Hsu YH et al. Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8102 residents in an arseniasis-endemic area in northeastern Taiwan. Am J Epidemiol 2001 153 : 411 8
11. Weyer PJ, Cerhan JR, Kross BC et al. Municipal drinking water nitrate level and cancer risk in older women: the Iowa Women's Health Study. Epidemiology 2001 12 : 327 38
12. Lamm SH, Engel A, Kruse MB et al. Arsenic in drinking water and bladder cancer mortality in the United States: an analysis based on 133 U.S: counties and 30 years of observation. J Occup Environ Med 2004 46 : 298 306
13. Ward MH, Cantor KP, Riley D, Merkle S, Lynch CF. Nitrate in public water supplies and risk of bladder cancer. Epidemiology 2003 14 : 183 90
14. Jung I, Reeder JE, Cox C et al. Chromosome 9 monosomy by fluorescence in situ hybridization of bladder irrigation specimens is predictive of tumor recurrence. J Urol 1999 162 : 1900 3
15. Bruno S, Torrisi R, Costantini M et al. Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial. J Cell Biochem 1999 76 : 311 21
16. Hemstreet GP 3rd, Yin S, Ma Z et al. Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine. J Natl Cancer Inst 2001 93 : 427 36
17. Hemstreet GP 3rd, Rao J, Hurst RE, Bonner RB, Mellott JE, Rooker GM. Biomarkers in monitoring for efficacy of immunotherapy and chemoprevention of bladder cancer with dimethylsulfoxide. Cancer Detect Prev 1999 23 : 163 71
18. Allard P, Bernard P, Fradet Y, Têtu B. The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br J Urol 1998 81 : 692 8
19. Grubbs CJ, Moon RC, Squire RA et al. 13-cis-Retinoic acid. inhibition of bladder carcinogenesis induced in rats by N-butyl-N-(4-hydroxybutyl) nitrosamine. Science 1977 198 : 743 4
20. Becci PJ, Thompson HJ, Grubbs CJ et al. Inhibitory effect of 13-cis-retinoic acid on urinary bladder carcinogenesis induced in C57BL/6 mice by N-butyl-N-(4-hydroxybutyl)-nitrosamine. Cancer Res 1978 38 : 4463 6
21. Zou C, Liebert M, Grossman HB, Lotan R. Identification of effective retinoids for inhibiting growth and inducing apoptosis in bladder cancer cells. J Urol 2001 165 : 986 92
22. Sabichi AL, Xu H, Fischer S et al. Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites. Clin Cancer Res 2003 9 : 4606 13
23. Zeegers MP, Goldbohm RA, van den Brandt PA. Are retinol, vitamin C, vitamin E, folate and carotenoids intake associated with bladder cancer risk? Results from the Netherlands Cohort Study. Br J Cancer 2001 85 : 977 83
24. Michaud DS, Pietinen P, Taylor PR, Virtanen M, Virtamo J, Albanes D. Intakes of fruits and vegetables, carotenoids and vitamins A, E, C in relation to the risk of bladder cancer in the ATBC cohort study. Br J Cancer 2002 87 : 960 5
25. Castelao JE, Yuan JM, Gago-Dominguez M et al. Carotenoids/vitamin C and smoking-related bladder cancer. Int J Cancer 2004 110 : 417 23
26. Studer UE, Jenzer S, Biedermann C et al. Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland. Eur Urol 1995 28 : 284 90
27. Sabichi AL, Lerner SP, Atkinson EN et al. Phase III prevention trial of fenretinide in patients with resected non muscle-invasive bladder cancer. Clin Cancer Res 2008 14 : 224 9
28. Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Willett WC, Giovannucci E. Prospective study of dietary supplements, macronutrients, micronutrients, and risk of bladder cancer in US men. Am J Epidemiol 2000 152 : 1145 53
29. Bruemmer B, White E, Vaughan TL, Cheney CL. Nutrient intake in relation to bladder cancer among middle-aged men and women. Am J Epidemiol 1996 144 : 485 95
30. Lamm DL, Riggs DR, Shriver JS, vanGilder PF, Rach JF, DeHaven JI. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 1994 151 : 21 6
31. Shibata MA, Hasegawa R, Shirai T, Takesada Y, Fukushima S. Chemoprevention by indomethacin of tumor promotion in a rat urinary bladder carcinogenesis model. Int J Cancer 1993 55 : 1011 7
32. Mohammed SI, Bennett PF, Craig BA et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 2002 62 : 356 8
33. Shariat SF, Kim JH, Ayala GE, Kho K, Wheeler TM, Lerner SP. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol 2003 169 : 938 42
34. Sheehy OE, Zhao SZ, Raymoundo AL, Miller B, Aprikian AG, Lelorier J. Celecoxib associated with reduced risk of superficial bladder cancer (SBC) recurrence. Proc Am Soc Clin Oncol 2003 22 : 383, Abstract 1539
35. Smith MK, Goral MA, Wright JH et al. Ornithine decarboxylase overexpression leads to increased epithelial tumor invasiveness. Cancer Res 1997 57 : 2104 8
36. Messing EM, Hanson P, Reznikoff CA. Normal and malignant human urothelium: in vitro response to blockade of polyamine synthesis and interconversion. Cancer Res 1988 48 : 357 61
37. Messing E, Kim KM, Sharkey F et al. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol 2006 176 : 500 4
38. Mokhtar NM, el-Aaser AA, el-Bolkainy MN, Ibrahim HA, el-Din NB, Moharram NZ. Effect of soybean feeding on experimental carcinogenesis - III. Carcinogenecity of nitrite and dibutylamine in mice: a histopathological study. Eur J Cancer Clin Oncol 1988 24 : 403 11
39. Yoshida O, Brown RR, Bryan GT. Relationship between tryptophan metabolism and heterotopic recurrences of human urinary bladder tumors. Cancer 1970 25 : 773 80
40. Byar D, Blackard C. Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer. Urology 1977 10 : 556 61
41. Newling DW, Robinson MR, Smith PH et al. Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladde cancer. Results of a prospective, randomized phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group. Eur Urol 1995 27 : 110 6